New plant expected to cut drug costs
News
By
Esther Dianah
| Nov 07, 2021
Square Pharmaceuticals Kenya EPZ Ltd, an investment of Bangladesh-based Square Pharmaceuticals Ltd is set to open a manufacturing plant at EPZ.
The plant is projected to reduce the cost of medicines in the East African Community (EAC) region and would export 50 per cent of its products to African markets. It will also provide 1,000 direct jobs.
The plant, which is the first phase of a total $75 million (Sh8 billion) investment by the Bangladeshi company is aligned to the World Health Organisation's global cost-reduction strategy, aimed at promoting technology transfer between developed and developing countries.
This is targeted at bringing down the price of drugs and increasing public access to quality and affordable medicines in the region.
The plant which sits on 6.03 hectares of land with a production capacity of over two billion capsules and tablets annually, is the first investment that the Bangladesh government approved to be located in Africa.
READ MORE
Stocks rise as optimism over Mideast war takes hold
New 2030 plan targets billions in financing for farmers and MSMEs
Three Kenyan startups picked for Africa eye health accelerator
Maina named Vision 2030 acting director
Kenyan firms eye Caribbean footprint as Afreximbank seals St Kitts trade forum deal
Experts say Ruto is driving economy to the ground over rising fuel prices
New Kifwa team takes office after chaotic polls
Beyond Mombasa: Why Kenya must rethink its port strategy
Dock worker Owuor ousts Sang, ends 20-year rule at union
State's affordable housing project: Why Kenyans are sceptical
Speaking during a familiarisation tour at the plant, Industrialisation, Trade and Enterprise Development CS Betty Maina said the government was keen on supporting the establishment and growth of the Pharma manufacturing sector. This, she noted would improve the lives of Kenyans, create jobs and strengthen local value chains.
Square Pharmaceuticals Ltd Managing Director Tapan Chowdhury lauded the State's support for the pharmaceutical industry. “We believe that local pharmaceutical production has a potential to reduce the cost of drugs by 40 per cent,” Tapan said.